Theravance Biopharma Q1 2023 net loss narrows to $22.1M; YUPELRI sales up 8% to $47M

Theravance Biopharma, Inc.

2023-Q1 EPS reported -$0.35 revenue$10,417,000

Q1 GAAP net loss from continuing ops $22.1M vs $40.3M; non-GAAP net loss $14.9M vs $25.2M.
YUPELRI net sales (Viatris) $47M, +8% YoY; Theravance's 35% share $16.4M.
$215M of $325M buyback completed; $110M remaining; on track to finish by year-end.
CYPRESS Phase 3 study of ampreloxetine in MSA-nOH actively recruiting; enrollment expected H2 2024.
Jim Kelly (Weiss Asset Mgmt) appointed to Board; TRELEGY milestone $50M if 2023 global sales ≥ $2.9B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theravance Biopharma, Inc. reported the first quarter of 2023 results: revenue $10.4 million.

Period: the first quarter of 2023
Revenue: $10.4 million
Result: reported results

Exact text from the filing

Total revenue for the first quarter of 2023 was $10.4 million

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-057152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.